Transthyretin amyloid cardiomyopathy (ATTR-CM) is a condition that can lead to the heart not pumping well. Attruby (acoramidis) was approved in 2024 by the FDA to treat people with ATTR-CM. It has ...

Attruby (acoramidis) is a prescription drug that’s used to treat transthyretin amyloid cardiomyopathy (ATTR-CM). Attruby comes as an oral tablet. Attruby is prescribed for adults to treat ATTR-CM. To ...

The cost of Attruby can vary based on several factors, including your insurance coverage. Coupons and drug savings programs can also lower the price you’ll pay for Attruby. As with all medications, ...

An intriguing battle is brewing in the market to treat patients with transthyretin amyloid cardiomyopathy (ATTR-CM). It pits heavyweight champion Pfizer, middleweight contender Alnylam and feisty new ...

Despite formidable competition in the growing transthyretin amyloid cardiomyopathy (ATTR-CM) market, a strong early launch phase for BridgeBio Pharma’s Attruby is proving that the drug shouldn't be ...

BridgeBio reports strong demand for Attruby post-FDA approval and enrollment completion in three Phase 3 trials, with significant financial backing. BridgeBio Pharma, Inc. announced significant ...

As with other drugs, Attruby (acoramidis) can cause side effects, such as diarrhea. If Attruby’s side effects become difficult to tolerate, talk with your doctor or pharmacist. Attruby (acoramidis) is ...

The company reiterated its goal of achieving "30-plus percent market share by volume in the years to come" for Attruby. Kumar stated, "The obvious growth in our portfolio today sits with the expansion ...